Log in  First Connection?

Prostate Cancer & BPHArchives

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making

 Published on 29/05/2026 |  Original article (Full-text)  | Lilia Bardoscia et al. | Expert Review of Clinical Pharmacology 2026; aop:10.1080/17512433.2026.2677891

Prostate cancer is well known to be androgen-dependent, with growth directly relying on the androgen receptor signaling pathway. In fact, androgen deprivation therapy, with or without Docetaxel and/or newer hormonal drugs such as Abiraterone acetate, Enzalutamide, Apalutamide, and Darolutamide, remains...

Fusion genes in precision oncology: prostate cancer as a diagnostic case study

 Published on 22/05/2026 |  Original article (Full-text)  | Rebecca A. Morgan et al. | Expert Review of Molecular Diagnostics 2026; 26(5): 379-393

Fusion genes represent one of the most specific molecular alterations in human cancer and have long served as important diagnostic and therapeutic biomarkers. Advances in next-generation sequencing have driven a rapid expansion in fusion gene discovery. Clinical translation has lagged however, particularly...

Drinking water nitrate, disinfection byproducts, and prostate cancer incidence in the Agricultural Health Study

 Published on 15/05/2026 |  Original article (Full-text)  | Maya Spaur et al. | Journal of the National Cancer Institute. Volume 118(4).

Drinking water can be an important source of exposure to nitrate and disinfection by-products, including trihalomethanes (THMs) and haloacetic acids (HAAs). N-nitroso compounds formed endogenously after nitrate ingestion are animal carcinogens, and THM and HAA exposures increase the risk of some cancers....

Long-term performance of the Gleason score in predicting metastatic and fatal prostate cancer

 Published on 08/05/2026 |  Original article (Full-text)  | Zhike Lin et al. | American Journal of Epidemiology. Volume 195(4).

The time dependence in the performance of prognostic factors for cancer survival is typically incompletely understood, including in prostate cancer. We applied a "cumulative/dynamic" time-varying area under the curve (tAUC) for cumulative incidence of lethal prostate cancer (metastases/cancer-specific...

Guideline-based physical activity and health-related quality of life among prostate cancer survivors: a target trial emulation in the Health Professionals Follow-up Study

 Published on 01/05/2026 |  Original article (Full-text)  | Naiyu Chen et al. | American Journal of Epidemiology. Volume 195(4).

Prostate cancer and its treatment can impact health-related quality of life. Evidence for physical activity strategies sustained over long periods to improve quality of life is limited. Given the limited feasibility of a randomized trial to answer this question, we emulated a target trial of physical...